CanBas Co., Ltd. is a drug discovery company dedicated to research and development into anticancer agents in the field of immuno-oncology. CanBas possesses a proprietary drug discovery platform enabling in-house development of technologies and products through a combination of basic research and clinical research. As an R&D-based drug discovery company, in principle CanBas conducts early-stage (Phase 1) clinical trials internally, then out-licenses drug candidates to pharmaceutical companies for late-stage (Phase 2 and 3) programs requiring heavy expenditure.